(A) *Dogs*. 0.25 to 1 mg.
(B) *Cats*. 0.125 to 0.5 mg.
(C) *Horses*. 2.5 to 5 mg.
(D) *Cattle*. 5 to 20 mg, depending on the severity of the condition.
(ii) *Indications for use*. The drug is indicated:
(A) For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses;
(B) As an anti-inflammatory agent in dogs and cats.
(iii) *Limitations*. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(b)(1) *Specifications*. Each milliliter of solution contains 2.0 mg of dexamethasone or 4.0 mg of dexamethasone sodium phosphate (equivalent to 3.0 mg dexamethasone).
(2) *Sponsor*. See No. 061133 in § 510.600(c) of this chapter.
(3) *Conditions of use*—(i) *Amount*. Administer 0.25 to 1 mg by intravenous injection, repeated for 3 to 5 days or until a response is noted.
(ii) *Indications for use*. For use in dogs for the treatment of inflammatory conditions, as supportive therapy in canine posterior paresis, as supportive therapy before or after surgery to enhance recovery of poor surgical risks, and as supportive therapy in nonspecific dermatosis.
(iii) *Limitations*. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(c)(1) *Specifications*. Each milliliter of solution contains 2.0 mg of dexamethasone or 4.0 mg of dexamethasone sodium phosphate (equivalent to 3.0 mg of dexamethasone).
(2) *Sponsor*. See No. 061133 in § 510.600(c) of this chapter.
(3) *Conditions of use*—(i) *Amount*. Administer 2.5 to 5.0 mg by intravenous injection.
(ii) *Indications for use*. For use in horses as a rapid adrenal glucocorticoid and/or anti-inflammatory agent.
(iii) *Limitations*. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(d)(1) *Specifications*. Each milliliter of solution contains 2.0 mg of dexamethasone or 4.0 mg of dexamethasone sodium phosphate (equivalent to 3.0 mg of dexamethasone).
(2) *Sponsors*. See the following numbers in § 510.600(c) of this chapter:
(i) Nos. 016592 and 051031 for intravenous or intramuscular use of 2.0 milligrams dexamethasone injection.
(ii) No. 054771 for intravenous use of 2.0 milligrams dexamethasone injection.
(3) *Conditions of use*—(i) *Amount*. Administer by intravenous or intramuscular injection as follows:
(A) *Dogs:* 0.25 to 1 mg.
(B) *Cats:* 0.125 to 0.5 mg.
(C) *Horses:* 2.5 to 5 mg.
(ii) *Indications for use*. For use in dogs, cats, and horses as an anti-inflammatory agent.
(iii) *Limitations*. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(e)(1) *Specifications*. Each milliliter of solution contains 4.0 mg of dexamethasone sodium phosphate (equivalent to 3.0 mg dexamethasone).
(2) *Sponsor*. See No. 069043 in § 510.600(c) of this chapter.
(3) *Conditions of use*—(i) *Amount*. Administer by intravenous injection as follows:
(A) *Dogs:* 0.25 to 1 mg; may be repeated for 3 to 5 days.
(B) *Horses:* 2.5 to 5 mg.
(ii) *Indications for use*. For use in dogs and horses for glucocorticoid and anti-inflammatory effect.
(iii) *Limitations*. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[41 FR 28265, July 9, 1976]

EDITORIAL NOTE: For FEDERAL REGISTER citations affecting § 522.540, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and at *www.govinfo.gov*.

§ 522.558 Dexmedetomidine.

(a) *Specifications*. Each milliliter of solution contains:
(1) 0.1 milligrams (mg) dexmedetomidine hydrochloride; or
(2) 0.5 mg dexmedetomidine hydrochloride.
(b) *Sponsors*. See sponsors in in § 510.600(c) of this chapter for use as in paragraph (c) of this section:

(1) Nos. 017033, 068504, 069043, and 086117 for use of product described in paragraph (a)(2) of this section.

(2) No. 052483 for use of products described in paragraph (a) of this section.

(c) *Conditions of use*—(1) *Dogs*—(i) *Indications for use and amount.* (A) For use as a sedative and analgesic to facilitate clinical examinations, clinical procedures, minor surgical procedures, and minor dental procedures, administer 375 micrograms (µg) per square meter (/m^2) of body surface area by intravenous injection or 500 µg/m^2 of body surface area by intramuscular injection.

(B) For use as a preanesthetic to general anesthesia, administer 125 µg/m^2 of body surface area or 375 µg/m^2 of body surface area by intramuscular injection.

(ii) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) *Cats*—(i) *Amount.* 40 µg/killogram by intramuscular injection.

(ii) *Indications for use.* For use as a sedative and analgesic to facilitate clinical examinations, clinical procedures, minor surgical procedures, and minor dental procedures; and as a preanesthetic to general anesthesia.

(iii) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[72 FR 263, Jan. 4, 2007, as amended at 72 FR 19797, Apr. 20, 2007; 72 FR 51365, Sept. 7, 2007; 75 FR 60308, Sept. 30, 2010; 78 FR 25183, Apr. 30, 2013; 78 FR 33699, June 5, 2013; 80 FR 13229, Mar. 13, 2015; 86 FR 57997, Oct. 20, 2021; 87 FR 10969, Feb. 28, 2022; 88 FR 27699, May 3, 2023; 88 FR 84701, Dec. 6, 2023]

§ 522.563 Diatrizoate.

(a) *Specifications.* Each milliliter of solution contains 34.3 percent diatrizoate meglumine and 35 percent diatrizoate sodium, or 66 percent diatrizoate meglumine and 10 percent diatrizoate sodium.

(b) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.

(c) *Conditions of use in dogs and cats*—(1) *Amount.* For excretion urography, administer 0.5 to 1.0 milliliter (mL) per pound of body weight to a maximum of 30 mL intravenously. For cystography, remove urine, administer 5 to 25 mL directly into the bladder via catheter. For urethrography, administer 1.0 to 5 mL via catheter into the urethra to provide desired contrasts delineation. For angiocardiography (including aortography) rapidly inject 5 to 10 mL directly into the heart via catheter or intraventricular puncture. For cerebral angiography, rapid injection of 3 to 10 mL via carotid artery. For peripheral arteriography and/or venography and selective coronary arteriography, rapidly inject 3 to 10 mL intravascularly into the vascular bed to be delineated. For lymphography, slowly inject 1.0 to 10 mL directly into the lymph vessel to be delineated. For arthrography, slowly inject 1.0 to 5 mL directly into the joint to be delineated. For discography, slowly inject 0.5 to 1.0 mL directly into the disc to be delineated. For sialography, slowly inject 0.5 to 1.0 mL into the duct to be delineated. For delineation of fistulous tracts, slowly inject quantity necessary to fill the tract. For delineation of peritoneal hernias, inject 0.5 to 1.0 mL per pound of body weight directly into the peritoneal cavity.

(2) *Indications for use.* For visualization in excretion urography, including renal angiography, uretography, cystography, and urethrography; aortography; angiocardiography, peripheral arteriography, and venography; selective coronary arteriography; cerebral angiography; lymphography; arthrography; discography; and sialography; and as an aid in delineating peritoneal hernias and fistulous tracts.

(3) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16186, Mar. 25, 2014]

§ 522.650 Dihydrostreptomycin sulfate injection.

(a) *Specifications.* Each milliliter contains dihydrostreptomycin sulfate equivalent to 500 milligrams of dihydrostreptomycin.

(b) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.

(c) *Related tolerance.* See § 556.200 of this chapter.

(d) *Conditions of use*—(1) *Amount.* Administer 5 milligrams per pound of body weight by deep intramuscular injection every 12 hours, for 3 to 5 days or